• Je něco špatně v tomto záznamu ?

Serological response to HPV16 in CIN-III and cervical cancer patients. Case-control studies in Spain and Colombia

Sanjose S De, E Hamsikova, N Munoz, FX Bosch, V Hofmannova, M Gili, I Izarzugaza, P Viladiu, MJ Tormo, P Moreo, MT Munoz, N Ascunce, L Tafur, KV Shah, V Vonka

. 1996 ; 66 (1) : 70-74.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc13009292

Grantová podpora
IZ1914 MZ0 CEP - Centrální evidence projektů

Digitální knihovna NLK
Plný text - Část
Zdroj

E-zdroje Online Plný text

NLK Wiley Online Library (archiv) od 1996-01-01 do 2012-12-31

Odkazy

PubMed 8608970
Knihovny.cz E-zdroje

This study evaluates the association of antibodies against HPV-16-derived peptides with cervical cancer and estimates the sensitivity and specificity of the serological assays in relation to HPV DNA detection in cervical cells by PCR. Study subjects were derived from 4 case-control studies carried out in Spain and Colombia. Sera from 544 cases of CIN III and invasive cancer and of 543 age-matched controls were tested for antibodies to 5 peptides derived from E2, E7 (3 partially overlapping frames of HPV 16 denoted E7/ 1, E7/2, E7/3) and L2 open reading frames of HPV 16. HPV DNA was detected using a L1-PCR based method. Among cancer controls, antibody response to E2 and E7/1, E7/2, E7/3 was higher in Colombia (22.5%,7.2%,11.7%,12.6% respectively) than in Spain (17.1 %, 4.7%, 5.9%, 5.9%). E7 antibodies were related to stage, particularly in CIN III vs. invasive stages and less markedly within invasive stages. Detection of antibodies to the E7/1 was associated to CIN III (OR = 1.8). The risk of invasive cervical cancer was increased among those with antibodies to E2 (OR = 2.2), to E7/1 (OR = 4.2), to E7/2 (OR = 4.3), and to E7/3 (OR = 2.5). Presence of antibodies to all the 3 E7 peptides increased the risk of CIN III (OR = 5.6) and that of invasive cancer (OR = 17.5). High levels of antibodies to E7/1 or E7/2 or E7/3 increased the risk of invasive cervical cancer (OR for high levels of antibodies vs. negatives to E7/1 OR = 22.6; E7/2 OR = 7.5, E7/3 OR = 3.4). In the present analysis, antibodies to L2 were not associated with either CIN III or cervical cancer. Serological markers of HPV 16 detected less than half of the HPV-16-DNA-positive cases. It is concluded that antibodies to E2 and particularly E7 antigens are strongly associated with cervical cancer. Antibodies to E7 seem to be a moderate marker of tumor burden.

Obsahuje tabulky

Bibliografie atd.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc13009292
003      
CZ-PrNML
005      
20130311151546.0
007      
ta
008      
130311s1996 xxu f 000 0|eng||
009      
AR
035    __
$a (PubMed)8608970
040    __
$a ABA008 $d ABA008 $e AACR2 $b cze
041    0_
$a eng
044    __
$a xxu
100    1_
$a De Sanjosé, Silvia $u Servei d'Epidemiologia i Registre del Cancer, Institut Catala d Oncologia, Barcelona, Spain
245    10
$a Serological response to HPV16 in CIN-III and cervical cancer patients. Case-control studies in Spain and Colombia / $c Sanjose S De, E Hamsikova, N Munoz, FX Bosch, V Hofmannova, M Gili, I Izarzugaza, P Viladiu, MJ Tormo, P Moreo, MT Munoz, N Ascunce, L Tafur, KV Shah, V Vonka
500    __
$a Obsahuje tabulky
504    __
$a Literatura
520    9_
$a This study evaluates the association of antibodies against HPV-16-derived peptides with cervical cancer and estimates the sensitivity and specificity of the serological assays in relation to HPV DNA detection in cervical cells by PCR. Study subjects were derived from 4 case-control studies carried out in Spain and Colombia. Sera from 544 cases of CIN III and invasive cancer and of 543 age-matched controls were tested for antibodies to 5 peptides derived from E2, E7 (3 partially overlapping frames of HPV 16 denoted E7/ 1, E7/2, E7/3) and L2 open reading frames of HPV 16. HPV DNA was detected using a L1-PCR based method. Among cancer controls, antibody response to E2 and E7/1, E7/2, E7/3 was higher in Colombia (22.5%,7.2%,11.7%,12.6% respectively) than in Spain (17.1 %, 4.7%, 5.9%, 5.9%). E7 antibodies were related to stage, particularly in CIN III vs. invasive stages and less markedly within invasive stages. Detection of antibodies to the E7/1 was associated to CIN III (OR = 1.8). The risk of invasive cervical cancer was increased among those with antibodies to E2 (OR = 2.2), to E7/1 (OR = 4.2), to E7/2 (OR = 4.3), and to E7/3 (OR = 2.5). Presence of antibodies to all the 3 E7 peptides increased the risk of CIN III (OR = 5.6) and that of invasive cancer (OR = 17.5). High levels of antibodies to E7/1 or E7/2 or E7/3 increased the risk of invasive cervical cancer (OR for high levels of antibodies vs. negatives to E7/1 OR = 22.6; E7/2 OR = 7.5, E7/3 OR = 3.4). In the present analysis, antibodies to L2 were not associated with either CIN III or cervical cancer. Serological markers of HPV 16 detected less than half of the HPV-16-DNA-positive cases. It is concluded that antibodies to E2 and particularly E7 antigens are strongly associated with cervical cancer. Antibodies to E7 seem to be a moderate marker of tumor burden.
590    __
$a bohemika - dle Pubmed
650    02
$a dospělí $7 D000328
650    12
$a protilátky virové $x imunologie $7 D000914
650    02
$a antigeny virové $x imunologie $7 D000956
650    12
$a karcinom $x imunologie $x mikrobiologie $7 D002277
650    02
$a karcinom in situ $x imunologie $x mikrobiologie $7 D002278
650    02
$a studie případů a kontrol $7 D016022
650    12
$a dysplazie děložního hrdla $x imunologie $7 D002578
650    02
$a ženské pohlaví $7 D005260
650    02
$a lidé $7 D006801
650    12
$a Papillomaviridae $x imunologie $7 D027383
650    12
$a nádory děložního čípku $x imunologie $x mikrobiologie $7 D002583
651    _2
$a Kolumbie $7 D003105
651    _2
$a Španělsko $7 D013030
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Hamšíková, Eva $7 xx0052821 $u Institute of Hematology and Blood Transfusion, Department of Experimental Virology, Prague, Czech Republic
700    1_
$a Munoz, Nubia $u Unit of Field and Intervention Studies, International Agency for Research on Cancer, Lyon, France
700    1_
$a Bosch, F. Xavier $u Servei d'Epidemiologia i Registre del Cancer, Institut Catala d Oncologia, Barcelona, Spain
700    1_
$a Hofmannová, Vanda $7 xx0074129 $u Institute of Hematology and Blood Transfusion, Department of Experimental Virology, Prague, Czech Republic
700    1_
$a Gili, Miguel $u Hospital Universitario Vitgen del Rocio, Sevilla, Spain
700    1_
$a Izarzugaza, Isabel $u Registro del Cancer de Euzkadi, Vitoria-Gasteiz, Spain
700    1_
$a Viladiu, Paul $u Unitat d'Epidemiolgia i Registre del Cancer, Girona, Spain; Servei d'Epidemiologia i Registre del Cancer, Institut Catala d Oncologia, Barcelona, Spain
700    1_
$a Tormo, Maria José $u Consejeria de Sanidad y Asuntos S'ociales, Murcia, Spain
700    1_
$a Moreo, Pilar $u Direction de Salud Publica, Diputación General de Aragón, Zaragoza, Spain
700    1_
$a Munoz, Maria Tereza $u Delcgación Territorial de Bienestar Social, Salamanca, Spain
700    1_
$a Ascunce, Nieves $u Departamento de Salud, Gobierno de Navarra, Pamplona, Spain $7 gn_A_00009222
700    1_
$a Tafur, Luis $u Universidad del Valle, Cali Colombia
700    1_
$a Shah, Keerti V. $u Johns Hopkins University, School of Hygiene and Public Health, Baltimore, Maryland, USA
700    1_
$a Vonka, Vladimír, $d 1930- $7 jk01150642 $u Institute of Hematology and Blood Transfusion, Department of Experimental Virology, Prague, Czech Republic
773    0_
$t International Journal of Cancer $x 0020-7136 $g Roč. 66, č. 1 (1996), s. 70-74 $p Int J Cancer $w MED00002298
773    0_
$p Int J Cancer $g 66(1):70-4, 1996 Mar 28 $x 0020-7136
910    __
$a ABA008 $b A 3679 $y 3 $z 0
990    __
$a 20130311082109 $b ABA008
991    __
$a 20130311151800 $b ABA008
999    __
$a ok $b bmc $g 972110 $s 807544
BAS    __
$a 3
BMC    __
$a 1996 $b 66 $c 1 $d 70-74 $i 0020-7136 $m International journal of cancer $x MED00002298 $n Int J Cancer
GRA    __
$a IZ1914 $p MZ0
LZP    __
$a 2013-03/gvbo

Najít záznam

Citační ukazatele

Možnosti archivace